Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP19A1 | P11511 | 16/20 | 0.53 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.46 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
| ▸ | S1PR3 | Q99500 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6222574 | 0.86 | CYP19A1 (0.49) | CYP19A1MEN1KMT2ACYP3A4MAPT | |
| SCHEMBL6202493 | 0.86 | MAPT (0.60) | CYP19A1MEN1KMT2ACYP3A4MAPT | |
| SCHEMBL10879896 | 0.85 | CYP19A1 (0.49) | CYP19A1MEN1KMT2ACYP3A4MAPT | |
| SCHEMBL6223782 | 0.82 | HSP90AA1 (0.53) | CYP19A1MEN1KMT2ACYP3A4CYP2C19 | |
| SCHEMBL10799731 | 0.78 | CYP19A1 (0.48) | CYP19A1MEN1KMT2ACYP3A4MAPT | |
| SCHEMBL8104836 | 0.78 | CYP19A1 (0.66) | CYP19A1CYP3A4CYP11B1TSHRCYP11B2 | |
| SCHEMBL11076165 | 0.77 | MAPT (0.59) | CYP19A1MEN1KMT2ACYP3A4TSHR | |
| SCHEMBL10418945 | 0.77 | HSP90AA1 (0.48) | CYP19A1MEN1KMT2ACYP3A4MAPT | |
| SCHEMBL10468609 | 0.77 | KMT2A (0.56) | CYP19A1MEN1KMT2ACYP3A4TSHR | |
| SCHEMBL6202608 | 0.76 | MAPT (0.67) | CYP19A1MEN1KMT2ACYP2C19MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050272036-A1 | Ketones | ASTRAZENECA AB (SE) | 2005-12-08 | — | — | US | disclosed |
| EP-1549600-A1 | KETONES | AstraZeneca AB (SE) | 2005-07-06 | — | — | EP | disclosed |
| US-6855710-B2 | Substituted indolines with an inhibitory effect on various kinases and complexes of CDKs | BOEHRINGER INGELHEIM PHARMA KG (DE) | 2005-02-15 | — | — | US | disclosed |
| US-20040058978-A1 | Novel substituted indolines with an inhibitory effect on various kinases and complexes of CDKs | BOEHRINGER INGELHEIM PHARMA KG (DE) | 2004-03-25 | — | — | US | disclosed |
| WO-2004011410-A1 | CHEMICAL COMPOUNDS | ASTRAZENECA AB (SE) | 2004-02-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040058978-A1 | Novel substituted indolines with an inhibitory effect on various kinases and complexes of CDKs | CDK1, CDK2, CDK3 | CYP19A1 556/4885MEN1 3345/4885KMT2A 750/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.